Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9ULP9
UPID:
TBC24_HUMAN
Alternative names:
-
Alternative UPACC:
Q9ULP9; A0JNW3; B9A6M6; Q2KJ08
Background:
TBC1 domain family member 24 plays a pivotal role in neuronal projections development and synaptic vesicle trafficking, acting as a GTPase-activating protein for Rab family proteins. Its involvement in modulating ARF6 function underscores its importance in neural connectivity and signal transmission.
Therapeutic significance:
Linked to a spectrum of neurological disorders, including familial infantile myoclonic epilepsy, developmental and epileptic encephalopathy, and various forms of deafness, TBC1 domain family member 24's study offers a promising avenue for therapeutic interventions targeting these debilitating conditions.